HearingNCT07254442
Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing
An observational study of Hearing and COVID - 19, run by Zonguldak Bulent Ecevit University at 1 site in Turkey (Türkiye).
Trial summary
Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Hearing, COVID - 19, Ototoxicity
- What is being tested?
- Hearing tests
- How many people
- 90 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Dec 2021to 1 Mar 2022
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: 1. Those who have had COVID-19 and are taking medication 2. Those who have had COVID-19 and are not taking medication 3. Healthy individuals who have not had COVID-19
Who may be able to join
- Age between 18 and 35 For the Medication group: Having had COVID-19 and using COVID-19 medications For the Non-Medication group: Having had COVID-19 and not using COVID-19 medications For the Control group: Having never had COVID-19
Who cannot join
- Previously diagnosed with hearing loss Use of ototoxic medications other than those specified Pathology detected during tympanometric evaluation or otoscopic examination Chronic disease Family history of hearing loss History of meningitis Neurological disorders Acute or chronic ear infection Admission to intensive care
Trial locations and contacts
1 site in 1 country.
About this study
Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing
Read the detailed description
This study aims to investigate the impact of medications containing the active ingredients hydroxychloroquine and favipiravir on the auditory system, as well as to examine the effect of COVID-19 on hearing and its potential relationship with medication use and COVID-19 vaccine dose.
- Conditions
- Hearing, COVID - 19, Ototoxicity
- Being tested
- Hearing tests
- Medical subject headings
- COVID-19, Ototoxicity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hearing testsDiagnostic test
Participants' pure tone thresholds, high frequency thresholds, and otoacoustic emissions measurements were evaluated.
| Study group | Role | What they receive |
|---|---|---|
| Control group | Group that has not had Covid-19 Receives: Diagnostic Test: Hearing tests | |
| Medication Group | The group that had Covid-19 and used medication Receives: Diagnostic Test: Hearing tests | |
| Non-medication group | The group that had Covid-19 and did not use medication Receives: Diagnostic Test: Hearing tests |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pure tone and high frequency hearing thresholds
Measured: December, 2021-February 2022
Transient evoked otoacoustic emissions - Signal/noise ratio
Measured: December, 2021-February 2022
Distortion product otoacoustic emissions- signal/noise ratio
Measured: December, 2021-February 2022
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Nov 2025
- Study start1 Dec 2021
- Primary completion1 Feb 2022
- Study completion1 Mar 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HearingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zonguldak Bulent Ecevit University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Azize Arzu KÖROĞLU KOÇYİĞİT, Zonguldak Bulent Ecevit University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07254442
- Sponsor's protocol ID
- 2021/61-18
- Other IDs
- 1919B012102481
- Status last verified
- Nov 2025
- First submitted
- 26 Sep 2025
- Last updated
- 28 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No